Related Experiment Video
Updated: Aug 11, 2026
05:09
Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
Published on: November 25, 2012
33.6K
INTRAVITREAL RANIBIZUMAB IN PREGNANT PATIENT WITH MYOPIC CHOROIDAL NEOVASCULAR MEMBRANE. A CASE REPORT
Summary
Intravitreal ranibizumab improved vision and reduced macular edema in a pregnant patient with myopic choroidal neovascularization (mCNV). The treatment showed no adverse effects on the pregnancy or newborn, but risk-benefit discussions are crucial.
Area of Science:
- Ophthalmology
- Medical Retina
- Pregnancy and Vision
Background:
- Myopic choroidal neovascularization (mCNV) poses a risk to vision, particularly in pregnant individuals.
- Management of mCNV during pregnancy requires careful consideration of maternal and fetal well-being.
Observation:
- A 34-year-old pregnant patient presented with mCNV in her third trimester, experiencing decreased visual acuity and macular edema.
- Initial treatment with intravitreal ranibizumab in the third trimester led to visual and anatomical improvements.
Findings:
- The patient received a second intravitreal ranibizumab injection early in a subsequent pregnancy, resulting in improved visual acuity and reduced macular edema.
- Both pregnancies resulted in healthy newborns with normal postnatal adaptation, despite the ranibizumab treatment during the first pregnancy.
Implications:
- Intravitreal ranibizumab can be an effective treatment for mCNV during pregnancy, with no apparent adverse effects on fetal development or neonatal outcomes.
- Careful risk-benefit assessment and patient counseling are essential when considering anti-VEGF therapy in pregnant patients with mCNV.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...